



सत्यमेव जयते



क.रा.बी.नि.  
**ESIC**

**कर्मचारी राज्य बीमा निगम**  
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)  
**EMPLOYEES' STATE INSURANCE CORPORATION**  
(Ministry of Labour & Employment, Govt. of India)

**DG-ESIC CENTRAL RATE CONTRACT NO. – 169**  
**FOR SUPPLY OF DRUGS & DRESSINGS**

(VALID FROM 11<sup>th</sup> DECEMBER, 2025 to 10<sup>th</sup> DECEMBER, 2027)

DRUGS ACTING ON GENITO URINARY SYSTEM
DRUGS USED FOR ALLERGIC DISORDERS
DRUGS USED IN SKIN DISORDERS
ANTISEPTICS/DRESSING MATERIAL
VITAMINS AND MINERALS

STRICTLY FOR OFFICIAL USE

मुख्यालय/HEADQUARTERS'

कमरा नंबर 312 और 321, तीसरी मंजिल, पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002

Room No. 312 & 321, 3<sup>rd</sup> Floor, Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002

[www.esic.gov.in](http://www.esic.gov.in), ☎ 011-23604773, ✉ [dmc-rc@esic.gov.in](mailto:dmc-rc@esic.gov.in)



क.रा.बी.नि.  
E S I C

S.No.	Contents	Page No.
1.	Forwarding letter along with terms & conditions for operation of Rate Contract No. 169	1-12
2.	List of Approved Pharmaceutical firms of Rate Contract No. 169	13-17
3.	Indexing of approved Items	18-25
4.	Rate Schedule of Rate Contract No. 169	26-46

क.रा.बी.नि.  
E S I C



कर्मचारी राज्य बीमा निगम  
(श्रम एवं रोज़गार मंत्रालय, भारत सरकार)  
EMPLOYEES' STATE INSURANCE CORPORATION  
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS'  
पंचदीप भवन, सी.आई.जी मार्ग, नई दिल्ली -110 002  
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002 [www.esic.gov.in](http://www.esic.gov.in)  
☎011-23604773, ✉ [dmc-rc@esic.gov.in](mailto:dmc-rc@esic.gov.in)

No. U-25/12/165 to 169/2024-Medical.V (E-754406)/169 (RC-169)

Dated: 12.12.2025

From:

The Director General,  
E.S.I. Corporation,  
Panchdeep Bhawan,  
C.I.G Road,  
NEW DELHI - 110 002.

To

Director (Medical) Delhi/Noida  
Dean-PGIMSR's/ All ESIC Medical Colleges & Hospitals/Dental Colleges  
Medical Superintendent – All ESIC & ESIS Hospitals,  
Director, ESI Scheme – All States & UTs.

Sub: **PROCUREMENT OF DRUGS UNDER ESIC CENTRAL RATE CONTRACT NO. 169 FEFFECTIVE FROM 11.12.2025 TO 10.12.2027.**

Sir / Madam,

Please find enclosed a copy of the DG-ESIC Centralized Rate Contract duly adhering to Public Procurement (Preference to Make in India) Order, 2017 (as amended and revised till date) and related notifications from the relevant Nodal Ministry/ Department, finalized for supply of Drugs under the ESI Scheme in the country.

**Validity of this Rate Contract is for a period of two years i.e. w.e.f. 11.12.2025 TO 10.12.2027.**

Further, the following terms & conditions are issued to govern operation of the Rate Contract:

1. Immediately on receipt of this communication, the Chief Direct Demanding Officers- Medical Superintendent/Dean/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his/her behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs.

2. Supply orders will be placed by Medical Superintendents/Deans/Director, Insurance Medical Services of various States, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and / or wherever specifically provided in the terms & conditions of the Rate Contract. The Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract.
3. All the supply orders shall be signed only by the officers who have been duly authorized and included in the list of DDOs. **DDOs will send scanned copy of the Purchase Order mandatorily through email followed by speed post directly to the Approved Pharmaceutical Firm. The due date of delivery will be counted from the date of issuance of purchase order via email. It shall be the responsibility of DDOs to monitor the activity of placing purchase order via email/online module.**
4. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them.
5. The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report along with the comments and details as under: -

**PROFORMA FOR NON-SUPPLY REPORT**

R.C. No.	Item No. & Name of Drug	Name of firm	S.O. No. with Date	Preference (L1/L2/L3)	Qty. not supplied	Risk Purchase/ penalty levied	Payment if pending	Remarks
1.	2.	3.	4.	5.	6.	7.	8.	9.

6. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account.
7. It will be ensured before placing order by the Direct Demanding Officer that necessary funds are available and **payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills.**
8. Supply orders/Purchase order(s) will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers.



9. No guarantee can be given as to the minimum quantity which will be drawn against this contract but the approved Pharmaceutical firm will supply quantity as may be ordered by the Direct Demanding Officers during the currency of the contract.
10. The approved Pharmaceutical firm will supply the items immediately on demand or latest within six weeks of placing of supply order throughout the period of contract.
11. Supply orders/Purchase orders against the contract will be accepted as long as these reach the approved Pharmaceutical firm on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract.
12. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm to supply the item as per the specifications of the relevant rate contract.

### **SUPPLIES**

13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit.
14. During transit approved Pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply.
15. The prices approved are F.O.R. Destination per unit and are exclusive of GST except where indicated but inclusive of all charges for packing and forwarding.
16. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market.
17. **The approved** Pharmaceutical firm will have to supply drugs directly in the quantity ordered, to ESIC or ESIS Institutions. The approved Pharmaceutical firm shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons. In case, at any stage of the contract, it is found that the approved Pharmaceutical firm has appointed the distributors/dealers/third party agent for making supply or receiving of supply order against the contract, ESI Corporation will initiate the following actions against the approved Pharmaceutical firm(s):



- a. 100% forfeiture of Performance Security from the valid current all DG-ESIC Rate Contract(s).
- b. Blacklisting for participation in the future tender enquiries for all ESI Institutions for a period of two years prospectively.

18. Marking/Labelling:

Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under.

19. Packing:

- a) **It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted/rubber stamping with indelible ink clearly. Any consignment without such stamping will not be considered valid and will be rejected.**
- b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances.
- c) Supplies to be made in proper boxes.
- d) Liquid orals to be supplied only in glass/ plastic bottles conforming to Drugs & Cosmetics Act and rules made there under.
- e) Large volume parenterals to be supplied only in plastic bottles / polypacks conforming to Drugs & Cosmetics Act and rules made there under.
- f) **It should be ensured that only first use packaging material of uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract.**
- g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia.
- h) Packing should be able to prevent damage or deterioration during transit.
- i) All containers i.e. bottle, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. MRP should not be written on any labels otherwise it will be disqualified.
- j) All DGESIC approved pharmaceutical firm will make supply bearing Quick response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing as per Gazette Notification and CDSCO guidelines time to time (Where ever Applicable).

**20. Life Period :**

I:

- a) For Drugs having shelf life of Two years or less: As on the date of delivery, Drugs should not be older than one fourth (1/4) of its shelf life from the date of manufacture.
- b) For Drugs having shelf life more than Two years: As on the date of delivery, Drugs should not be older than one sixth (1/6) of its shelf life from the date of manufacture.
- c) Imported Drugs: As on the date of delivery, Drugs should have a minimum 50% of valid shelf life from the date of manufacture.

II.

Notwithstanding the above, DDOs/Authorized nominated officer by DDO may relax this criteria in case of exigencies with reasons duly recorded and shall be responsible for use of that stores within its given shelf life, with a suitable undertaking from the supplier, the terms of which shall be decided by the consignee as per the requirement of the stores and usage pattern. The Consignee should ensure that there should not be any financial loss to the Corporation.

**21. Pharmacopoeia Specifications:**

Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the formulation supplied as per the provisions of Drug and Cosmetics Act.

22. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order.

23. It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has ISI Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards (Where ever Applicable).

**24. Testing of Drugs – Quality Control**

- a. Approved Rate Contract Holder should mandatorily submit a Test Report for that particular batch of medicines tested by the Government/Government approved Laboratories along with each supply, failing which supply received will be liable for rejection at the inspection stage and penalty of late supply will be levied as per provisions.
- b. Regular testing of 10% of supplies of drugs received in a month will be under taken by ESI from Govt./Govt. approved laboratories. Additional quality testing may also be undertaken by ESI Institutions at any time during the shelf life or whenever any defect is noticed.



- c. Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the approved Pharmaceutical firm/ firms at regular interval to maintain and ensure the quality of drugs.
- d. Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action.
- e. The report of the Govt./Govt. approved laboratory shall be accepted by the approved Pharmaceutical firm. In case the same is disputed by the approved Pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However, the same should be submitted **within three months**, from the date of communication of the disputed test report to the approved Pharmaceutical firm. For this, the approved Pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory **at their own cost**. In case no response is received from the approved Pharmaceutical firm within the stipulated period, action as deemed fit as per terms & conditions of the Rate Contract will be initiated.
- f. For imported items: - The approved Pharmaceutical firm must submit the In-house test report of Principal manufacturer with each and every batch of supply.
- g. If any drug/s supplied against this Rate Contract are found to be "Not of Standard Quality" on inspection by Competent Authority, the approved Pharmaceutical firm will be liable to replace the entire quantity within 15 days otherwise risk purchase will be charged from the approved Pharmaceutical firm/s.
- h. If the product is found to be "Not of Standard Quality", the cost of testing will be recovered from the approved Pharmaceutical firms and further action will be taken as per clause no. 25 mentioned below:
25. The classification of defects into different categories is as per the guidelines issued by the Drugs Controller General (India), Central Drugs Standard Control Organization (CDSCO) & action will be taken by ESIC for each category of defects, described as below: -

**A. CATEGORY 'A' DEFECT (Spurious / Adulterated Drugs)-**

**If any item / Batch of the item declared Not of Standard quality (NSQ) under Category A .**

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Recoveries to be initiated by the DDO's wherever payment had been made already.
- **100% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for all the quoted drugs.



- Debarring of the Rate Contract holder /approved Pharmaceutical firm from current and all future DGESIC Rate Contract for participation in tender enquiry of all ESIC institutions prospectively for a period of two years.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug.

**B. CATEGORY 'B' DEFECT (Grossly Substandard Drugs):**

**1. If single item/ Batch of item is declared NSQ under Category B:**

- Recall of the NSQ item immediately from all ESIC & ESIS Institutions. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **20% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for that drug as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item.
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

**2.**

**a) If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category B**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **50% (20% + 30%) Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- Warning to be issued to the firm for the NSQ item
- Testing of the three subsequent supplies of the same item by the same firm (as declared NSQ) to be carried out by the same user unit from where the sample has been originally reported as NSQ.
- Cost of subsequent testing charges to be recovered from forthcoming bills of the approved Pharmaceutical firm.
- **Any subsequent (3<sup>rd</sup> onwards) NSQ reported** of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current and all future DGESIC Rate Contracts for a period of two years for participation in all ESI Institutions prospectively along with forfeiture of **100% performance security for all NSQ declared items.**

*J*

- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.
- b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category B within a year**
- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **100% Forfeiture of Performance Security from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.**
- Debarring of Rate Contract Holder/approved Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for the item for a period of two years for participation in all ESI Institution prospectively.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

#### **C. CATEGORY ' C' DEFECT (Minor Defects)**

##### **1.If single item/ Batch of item is declared NSQ under Category C**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

**2.**

##### **a)If more than one item supplied by individual approved Pharmaceutical firm is declared NSQ under Category-C.**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- Warning to be issued to the firm for the NSQ item.
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

##### **b) If more than one Batch of the same item belonging to any individual approved Pharmaceutical firm is declared NSQ under Category C within a year.**

- Recall of the NSQ item immediately from all ESIC & ESIS User Units. Replacement of items/ Recovery of payment to be initiated by the DDO"s (wherever payment had been made already).
- **10% Forfeiture of Performance Security** from the respective DGESIC Rate Contract for this item (2<sup>nd</sup> NSQ) as per clause 13(III) of TE.
- **Any subsequent (2<sup>nd</sup> NSQ onwards) NSQ** reported of the individual approved Pharmaceutical firm will lead to debarment for all the NSQ declared items from current DGESIC Rate Contracts.
- Warning to be issued to the firm for the NSQ item
- Rate Contract Holder/ approved Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs.

26. **Delivery Period – Risk Purchase**

- a. Delivery period will be of six weeks from the date of **issuance of purchase order via email** and the approved Pharmaceutical firm shall execute the order within stipulated time.
- b. If the approved Pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) percent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. An approved Pharmaceutical firm can seek extension of the delivery period with the prior consent of the Direct Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. The extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned DDO.
- c. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other approved Pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate or from local chemist. All DDOs of ESIC & ESIS Institutions shall record each instance of Non-Supply of respective approved Pharmaceutical Firm and a consolidated quarterly non-supply report to be submitted at ESIC HQRS.

**Extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer.**

- d. i) If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of approved Pharmaceutical firm. **The**



**extra expenditure involved in procuring supplies from elsewhere i.e. L2 firm/other running Govt. Contract/ Local Purchase etc. will be recoverable from the approved Non-supplying Pharmaceutical firm, in full by Direct Demanding Officers.**

ii) The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with bidder by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the bidder's Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than two years.

- e. If the approved Pharmaceutical firm fails to execute the supply order three times at any location of ESIC & ESIS in any part of the country during the period of rate contract, it shall be debarred for the next two years with effect from the last failure and forfeiting of Performance Security for that drug.

#### 27. Payment

Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the approved Pharmaceutical firm/bidder to supply the items as per the specifications of the relevant rate contract. No claim for the payment from contractor shall be entertained after the lapse of three years of arising of the claim.

- 28. Any dues or payments that have arisen to the Corporation from the approved Pharmaceutical firm for which no specific time limit has been laid down in the terms and conditions shall be payable by the approved Pharmaceutical firm within such time limit as may be prescribed in the letters/orders addressed to the approved Pharmaceutical firms.
- 29. Any payments that have been demanded as per the provisions of above-mentioned clause or under any other clause shall be payable within the time laid down. On failure to do so:
  - The approved Pharmaceutical firm shall be liable to be debarred for supplying items/ drugs etc. to the Corporation for a period not exceeding two years.
  - The Corporation reserves its right to take appropriate legal action against the defaulting firms as may be legally advised, including claim for compensation and damages for the period of delay and / or simple interest 10% per annum for each day of default.
- 30. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed: -

(a) Items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase.

(b) In case of items, where two approved Pharmaceutical Firms exist at L-1(1<sup>st</sup> Preference), it is mandatory for all Direct Demanding Officers (DDOs) to place Supply Orders in the ratio of 50% of the order quantity to each L-1 approved Pharmaceutical firm on each instance of placing of supply order. Same principal applies to L2 Firm(in case order is required to be placed with L2).

(c) For item No. 1394 in RC-169, L-2 firms are Class-I Local Suppliers & have agreed to match the price of L-1 bidder. Therefore 50% of the order quantity to each L-1 approved Pharmaceutical firm to be placed on each instance of placing of supply order.

31. No other document should be entertained for giving any cognizance for placing the supply orders.

32. The validity of the contract of approved Pharmaceutical firm holding Patent right of approved drug/s in the currency of Rate Contract shall be for two years or till date of expiry of patent whichever is earlier. It is the sole responsibility of the patent holding firm to mandatorily inform ESIC Ten days before the expiry of the Patent of the approved drug/s in Rate Contract, failing which the participating firm shall be blacklisted in the participating and prospective RCs for a period of two years along with forfeiture of EMD/ Performance security (as the case may be) as per Terms & Conditions of the Tender Enquiries.

33. The Letter of Award issued to the firms by this office cannot be used for placing orders.

34. Standing Committee on Government e-Market (SCoGeM), Ministry of Labour & Employment has granted exemption to publish and operate DG-ESIC Rate Contract for the Drugs other than drugs reserved for CPSUs.

35. Force Majeure:

If at any time during the applicability of Contract the bidder fails to discharge its Obligation due to force majeure (natural disaster or act of God etc.) he will promptly notify the Director General or its representative about the happening of such an event. The Director General or its representative is solely entitled to terminate/ determine the order/contract in respect of such performance of the bidder(s) obligations if he so desires. The obligations under the contract on behalf of bidder for the contract shall be resumed as soon as practicable after the event has come to an end or ceased to exist.

36. It shall be the sole responsibility of Medical Superintendents/Deans/Director (Medical) Delhi/Director (Medical) Noida/DIMS/AMO/ Head of Institutions of respective State to maintain

an optimum Inventory level with strict control as per ABC-VED matrix and ensure the drug formulary of the respective institution is followed in right earnest to provide medical services to ESI Beneficiaries.

37. All Deans/MSs/DIMS/Head of ESIC & ESIS Institutions are requested to keep a vigilant check on procurement of drugs (strictly monitor Re-Order Level, Buffer Stock, Lead Time etc.) in order to avoid obsolescence/expiry/excessive procurement of drugs resulting in infructuous expenditure.


**This issue with the approval of Competent Authority.**

Encl.: As above.


Copy to:

1. PPS/PS to Director General, ESIC for information.
2. PPS/PS to Finance Commissioner for information.
3. PPS/PS to Medical Commissioner (Procurement/ Medical Administration) for information.
4. Accounts Branch – V (Hqrs. Office)
5. All Chief Direct Demanding Officers (In-Charge) of ESIC and ESI Scheme of all States/UT's for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract.
6. Website Content Manager for uploading on ESIC HQRS Website.
7. Guard File.

Yours faithfully,

  
(Dr. Sanjiv Kochhar)  
Dy. Medical Commissioner (RC)  
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar  
उप विक्ता आयुक्त / Deputy Medical Commissioner  
क.रा.बी.नि.(मु.) / E.S.I.C. (H.Q.)  
श्रम एवं रोजगार मंत्रालय, भारत सरकार  
Ministry of Labour & Employment, Govt. of India  
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02  
Panchdeep Bhawan, C.I.G. Road, New Delhi-02

  
(Dr. Sanjiv Kochhar)  
Dy. Medical Commissioner (RC)  
For: DIRECTOR GENERAL

डॉ. संजीव कोचर / Dr. Sanjiv Kochhar  
उप विक्ता आयुक्त / Deputy Medical Commissioner  
क.रा.बी.नि.(मु.) / E.S.I.C. (H.Q.)  
श्रम एवं रोजगार मंत्रालय, भारत सरकार  
Ministry of Labour & Employment, Govt. of India  
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली-02  
Panchdeep Bhawan, C.I.G. Road, New Delhi-02



## List of Approved Pharmaceutical firms of Rate Contract No. 169

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
1.	169	ALPA LABORATORIES LTD	33/2, A.B. Road, Pigdamber 453 446, Indore (MP)	0731 4294567, 7415794617, tenders@alpalabs.in
2.	169	Bayer Pharmaceuticals Private Limited	Bayer House, Central Avenue, Hiranandani Estate, Thane (W) - 400607	022 2531 1234, 022 2545 5063, 9811694231, yogesh.prakash@bayer.com
3.	169	Bharat Biotech International Limited.	BHARAT BIOTECH INTERNATIONAL LIMITED Sy. No. 230,231 & 235, Genome Valley, Turkapally (V), Shameerpet (M), Medchal-Malkajgiri (D)-500078, Telangana, India.	+91 4023480567, +91 4023480560, 9133334308, marketingis01@bharatbiotech.com, marketingis03@bharatbiotech.com
4.	169	Biodeal Pharmaceuticals Ltd.	Vill. Saini Majra, Nalagarh Ropar Road Nalagarh, Himachal Pradesh 174101	0120-6025048, 0120-6025048, 7428744221, institution1@biodealpharma.com, Institution@biodealpharma.com
5.	169	Brawn Laboratories Limited	Brawn laboratories Limited, Plot No. 44 Pace city-1, Sector-37, Gurgaon-122001 (Haryana)	0124-2970224, 0124-2970224, 8800275984, inst@brawnlabs.in
6.	169	Cadila Pharmaceuticals Limited	Cadila Corporate Campus, Sarkhej Dholka Road, Bhat, Ahmedabad - 382 210, Gujarat.	02718- 351000, 02718 225039, 9970170264, 96190 63299, sandeep.mohan@cadilapharma.com, kular.singh@cadilapharma.com, uthaman.nair@cadilapharma.com
7.	169	Centaur Pharmaceuticals Pvt. Ltd.	Centaur House, A- Wing , Institutions Dept., Shanti Nagar, Vakola, Santacruz East Mumbai -400055	022-66499270/274, 022-66499112, 98202244293 / 9930593597, institutions@centaurilab.com, sameer@centaurilab.com
8.	169	Cipla Ltd.	Cipla House Peninsula Business Park, Ganpatrao Kadam Marg, lower Parel, Mumbai- 400 013	022 24826000, 022 24826120, +91 9820273567, +91 9506692389, Institution@Cipla.com, vishwas.ahuja@cipla.com, prashant.gupta1@cipla.com, praveen.kumar18@cipla.com
9.	169	Dr. Reddy's Laboratories Limited	7-1-27, Ameerpet, Hyderabad-500016, Telangana, India.	040-49048400, 040-49048800, 91 9000995868 & 91 9154302501 , ibtpricing@drreddys.com, ibt@drreddys.com
10.	169	DWD Pharmaceuticals Ltd.	Dalamal House, 4th floor, Nariman Point, Mumbai - 400 021	022 - 2853910 / 11, 022 - 22825753, 9969006343, corporate@dwdindia.com, factory@dwdindia.com



## List of Approved Pharmaceutical firms of Rate Contract No. 169

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
11.	169	Eli Lilly and Company (India) Pvt. Ltd	Plot No. 92, Sector 32, Gurgaon - 122001, Haryana	0124 - 4753000, 0124 - 4753012, 9910897355, singh_inderpal@lilly.com, tendersinfo@lilly.com
12.	169	Emcure Pharmaceuticals Limited	EMCURE PHARMACEUTICALS LIMITED, BUILDING A-202 & 202, GANGA OSIAN SQUARE , WAKAD , PUNE -411057, MAHARASHTRA INDIA	020-35070033, 020-35070033, 9830890292/7428714333, institution@emcure.com, Niladri.Das@emcure.com
13.	169	Glenmark Pharmaceuticals Limited	Glenmark Pharmaceuticals Limited, Glenmark House, B.D.Sawant Marg, Chakala, Andheri East, Mumbai - 400099	022-40189999, 022-40189986, 9867027126, govt.tenders@glenmarkpharma.com
14.	169	HAB Pharmaceuticals & Research Ltd	A-301 PENINSULA BUSINESS PARK, GANPATRAO KADAM MARG LOWER PAREL MUMBAI 400013	022-66261409, 022-66261414, 9930212908, marketing@habpharma.in, institution@habpharma.in
15.	169	Hindustan Laboratories Limited	A-302, Victory Park, Chandavarkar Road, Borivali (West), Mumbai - 400092, Maharashtra	022-42460500, 42460526, 022-42460531, 7710055194, sales@hindlab.com, tender@hindlab.com, kunjaldedhia@hindlab.com
16.	169	Indoco Remedies Ltd.	Indoco Remedies Limited, Indoco House, 166, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098.	022 - 6287 1000/ 6817 1250, 022 - 2652 0884, 9004046733, mshetty@indoco.com, kiran.borle@indoco.com
17.	169	Jyoti Capsulations Private Limited	123/37, Saresh Bagh, Kanpur Uttar Pradesh - 208012	091-9956335559, 091-9792999909/ 9839035102, jcpl@jyotiacapsule.com
18.	169	LOGOS PHARMA	182/2, 3rd floor, Industrial area, Phase 1, Chandigarh-160002	0172-4822400, 6284300825, logos.tenders@gmail.com
19.	169	Macleods Pharmaceuticals Limited	Atlanta Arcade, Marol Church Road, Opposite Leela Hotel , Andheri (East), Mumbai - 400059	2266762672, 2229256599, 7304564056, tenders@macleodspharma.com
20.	169	MANKIND PHARMA LIMITED	M/s. Mankind Pharma Limited, 208, Okhla Industrial Estate, Phase-3, New Delhi-110020	011-46541400, 011-46541382, 9599911736, 9873661749, tender@mankindpharma.com, rajesh.h.kaul@mankindpharma.com, gaurav.saxena@mankindpharma.com
21.	169	MASCOT HEALTH SERIES PVT LTD	B-1/635, 2nd Floor, Near Janakpuri East Metro Station, Janakpuri, New Delhi 110058	011-28542407/08/10, 8800220714, gmsales.mkt@mascohealth.com, rk.c.mascohealth@gmail.com





ए.स.सी.सि.  
E S I C

### List of Approved Pharmaceutical firms of Rate Contract No. 169

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
22.	169	Med Manor Organics Pvt. Ltd.	16-11-477/45, Sri Krishna Nilyam, Dilsukh Nagar, Hyderabad - 500036	040-24053155 & 32934530, 040 - 24041284, 8898880276, yogendra.mishra@medmanor.in, ganesh.jayaraman@medmanor.in, esic@medmanor.in
23.	169	MICRO LABS LTD	No. 31, Race Course Road, Bangalore-560 001	: +91-80-2237 0451-57 line: +91-80-2237 0463 , 9350808984 ; 9591211411, rakeshsharma_micro@yahoo.co.in
24.	169	MICRON PHARMACEUTICALS	Plot No. 2117, A-2, Phase III GIDC Vapi 396 195	0260 2405400/405/407/412, 0260 2405419, 9924170750, sales@micronpharma.in, contactus@micronpharma.in, sales@micronpharma.in
25.	169	Morepen Laboratories Limited	2nd Floor, Tower - C, DLF Cyber Park, Udyog Vihar - III, Sector - 20, Gurugram - 122016 (Haryana)	0124 - 4892000, 0124 - 4892000, 9891759817, yadvinder.singh@morepen.com, institution@morepen.com
26.	169	Nanz Medscience Pharma Pvt. Ltd.	Rampurghat, Paonta Sahib-173025, District Sirmour, Himachal Pradesh	01704-227400, 9805070502, admin@nanzpharma.com, nanz@nanzpharma.com, tenders@nanzpharma.com
27.	169	Overseas Health Care Private Limited	M/s. OVERSEAS HEALTHCARE PRIVATE LIMITED, 335KM Milestone, National Highway No.1, P.O. Box 25, Phillaur, District Jalandhar, Punjab State	01826-222886, 01826-222885, 9872019733, info@overseashealthcare.co.in, dmo hcpl@gmail.com
28.	169	Primus Pharmaceuticals	Primus Pharmaceuticals, Sadhoura Road, Mouza Ogli Khari, Vill. Asgarpur Majra, Distt. Sirmour ,173030, H.P	9034004055, 7056797055, tenders@primuspharmaceutical.com, marketing@primuspharmaceutical.com
29.	169	Pulse Pharmaceuticals Pvt Ltd	Pulse Pharmaceuticals Pvt Ltd., Plot No: 18/1, Sector III, HUDA Techno Enclave, Hitech City, Hyderabad - 500 081.	91-40-23119992, 91-40-23119992, 9346155755, 9311083087, suresh@pulsepharma.net, dineshku mar@pulsepharma.net
30.	169	Raptakos, Brett & Company Limited	21A, Mittal Towers, 210, Nariman Point, Mumbai-400021	022-40856000, 022-40856020, 9953804709, pankaj.vig@raptakos.net
31.	169	RIVPRA FORMULATION PVT. LTD,	RIVPRA FORMULATION PVT. LTD. CORPORATE OFFICE: RADISSON BLU, KM TRADE TOWER, 11TH FLOOR,	(0120-4277177), 0120-4277177, 9999811834, 8800394441, tender@rivpraformulation.com, info@rivpraformulation.com



## List of Approved Pharmaceutical firms of Rate Contract No. 169

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
			OFFICE NO: 1008, H-3, KAUSHAMBI, GHAZIABAD-201010 (U.P)	
32.	169	Signature Phytochemical Industries	Signature Phytochemical Industries, A-301 Peninsula Business Park Ganpatrao Kadam Marg Lower parel Mumbai 400013	022-66261400, 022-6624141, 8976716569, marketing@signaturepi.in
33.	169	Tablets (India) Limited	# 72, Marshalls Road, "Jhaver Centre" R A Building, 4th Floor, Egmore, Chennai, 600 008	044 - 4205 0000, 044 - 2858 9090, hd@tabletsindia.com
34.	169	Theon Pharmaceuticals Limited	Plot no. 400, Industrial Area, Phase-1, Panchkula-134113	0172-5210200, 0172-5033851, 7696000688, tender@theonpharma.com, spsingh@theonpharma.com
35.	169	Tirupati Medicare Ltd.	Nahan Road, Paonta Sahib, Dist. Sirmour, Himachal Pradesh - 173025	9816700121, 9816700122, 7807880495, tina.issar@tirupatigroup.co.in
36.	169	TORQUE PHARMACEUTICALS PVT LTD	C-83 Industrial area Phase-7 Mohali-160055 Punjab	1724991500, 1724991500, 9875989452, manish.upadhyay@torquepharma.com
37.	169	Troikaa Pharmaceuticals Limited	Troikaa House - 1, Satya Marg, Bodakdev, Ahmedabad - 380054	079 26856242, 079 26856246, 7227069020, tenderorder@troikaapharma.com, head_inst@troikaapharma.com
38.	169	UNICURE INDIA LTD	C-21, 22 & 23, Sector-3, Noida-201301, distt. Gautam Budh Nagar. (U.P.)	0120-4786713, 0120-4320184, 9810337912, unicare@unicureindia.com, mkumar712@gmail.com
39.	169	USV Private Limited	USV Private Limited, Arvind Vithal Gandhi Chowk, B.S.D marg, Govandi Station Road, Govandi - East, Mumbai - 400088	022 - 2556 4048, 022 - 2558 4025, 9871594946, manoj.sharma@usv.in
40.	169	Wings Biotech LLP	J-13, Udyog Nagar Industrial Area, Near Peeragarhi Metro Station, Delhi- 110041	011-45922222, 9871112877, manager.govtupply@wingsbiotech.com, institution.exe@wingsbiotech.com, wingstender.co@gmail.com
41.	169	ZIM LABORATORIES LIMITED	Saddoday Gyan (Ground Floor), Opp. NADT Nelson Square, Nagpur-440013 (MS)	7122981960, 7118271470, 9818678219, tendercell@zimlab.in, admin01@zimlab.in, marketing@zimlab.in



## List of Approved Pharmaceutical firms of Rate Contract No. 169

S. No.	RC No.	Name of the Approved Pharmaceutical Firm	Contact details (Mobile Number and email address)	Address of Approved Pharmaceutical Firm
42.	169	Zuventus Healthcare Limited	Zuventus House, Plot Y2, CTS NO: 358/A2, Near Nahur Railway Station, Nahur (West), Mumbai- 400078	022 35060000, 022 20812898, 9054797511, Rajiv.Kumar@zuventus.com, sheetal.khanvilkar@zuventus.com
43.	169	Zydus Healthcare Limited	M/s. Zydus Healthcare Limited Zydus Tower, CTS No. 460/6, Village Pahadi, Opposite IB Patel Road, Goregaon E, Mumbai - 400063	91-22-62721700, 91-22-62721700, 9957194623, institutionsales@zyduslife.com
44.	169	Zydus Lifesciences Limited	Zydus Lifesciences Limited 4th Floor, "B" Wing, 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G.Highway, Ahmedabad - 382 481, Gujarat, India.	+91-079-71800000, 91-079-48040000, +91-079-71800192, +91-91-98723 14125, ZLL_Institution_Business@zyduslife.com, NishuS.Dubey@zyduslife.com

*(Handwritten mark)*

क.स.बी.नि.  
ESIC



**Index RC- 169**

S.No.	RC No.	Item No.	Item Name and Description
1.	169	107	Disodium Hydrogen Citrate Liquid- Each 5ml to contain: Disodium Hydrogen Citrate 1.25gm.,100ml Bottle
2.	169	122	Pheniramine Syp- Each 5ml to contain: Pheniramine Maleate 15mg.,100ml Bottle
3.	169	266	VITAMIN A & D Tab/ Cap- Each Tab/ Cap to contain : Vitamin-A 6000 IU, Vitamin-D 1000 IU
4.	169	267	Ferrous Sulphate Tab/Cap-Each Tab/Cap to contain: Ferrous Sulphate 200mg
5.	169	268	Iron & Folic Acid SR Tab/Cap- Each SR Tab/Cap to contain: Ferrous Sulphate 150mg. (in S.R. form), Folic acid 0.5mg
6.	169	411	Calamine Lotion- Each Bottle to contain: Calamine IP 15% w/v, Zinc Oxide IP 5% w/v, Bentonite IP 3% w/v, Sodium Citrate IP 0.05% w/v, Glycerin IP 5% w/v, lotion,100ml Bottle
7.	169	450	Vitamin Tab/Cap- Each Tab/Cap. To contain: Thiamine 10mg., Riboflavin 8mg., Pyridoxine 3mg., Vit.B125mcg., Niacinamide 50mg., Calcium Pantothenate 15mg., FolicAcid1mg., Ascorbic Acid 125mg.
8.	169	484	Povidone Iodine Dressing- Containing: Povidone Iodine 10% sterile dressing, Box of 20 dressings.
9.	169	519	Fluocinolone Oint-Each Tube to contain: Fluocinolone Acetonide 0.1%, Methyl Paraben 0.15%, Propyl Paraben 0.05%,15gm Tube
10.	169	559	Coal Tar + Salicylic Acid Soln/Lotion-Each Bottle to contain: Coal Tar Topical Sol. 4.25%, Salicylic Acid I.P. Sol. 2%, 60ml Bottle
11.	169	1246	Gamma Benzene Hexachloride Lotion- Each Bottle to Contain: Gamma Benzene Hexachloride 1%, 500ml Bottle
12.	169	1295	Iron TR Tab/Cap- Each TR Tab/cap to contain: Ferrous Fumarate 200mg., Cyanocobalamin 15mcg., Folic Acid 1.5mg
13.	169	1297	Folic Acid Tab/Cap-Each Tab/Cap to contain: Folic Acid 5 mg.
14.	169	1299	Cholecalciferol Granules, Each gm to contain: Vit. D3 60,000 IU,1gm Sachet
15.	169	1307	Mutivitamin+Zinc Cap/Tab-Each Cap/Tab to contain: Zinc Sulfate Monohydrate 61.8mg. (eqv. to 22.5mg. Of elemental Zinc). Vit. B1- 10mg., Vit. B6-2mg., Vit.B12-5mcg., Ca. Pantothenate 12.5mg., Vit. E Acetate 15mg., Vit. C 150mg., Nicotinamide 50mg. And Vit. B2- 10mg.



ए.स.ई.सी.  
E S I C

16.	169	1315	Amino Acid + Vitamin Cap/Tab-Each Cap/Tab to contain: L-Leucine 18.3mg.,L-Isoleucine 5.9mg.,L- LysineHydrochloride25.0mg.,L-Phenylalanine5.0mg.,L- Valine6.7mg.,L-Tryptophan5.0mg.,DL- Methionine18.4mg.,5-Hydroxy Anthranilic Acid Hydrochloride 0.2mg., Vit. A concentrate 2500IU,Vit D3 200IU, Thiamine Mono nitrate 5.0mg., Vit. B2 3.0mg. Nicotinamide 25mg.,Vit.B6 1.5mg.,Folic Acid 0.75mg.,Calcium Pantothenate IP 5.0mg.,Vit.B12 2.5mcg.,Vit.C 40.0mg., Vit. E acetate 7.5 IU, L-Threonine 4.2 mg.
17.	169	1364	Salicylic Acid+ Betamethasone Oint-Each Tube to contain: Betamethasone IP 0.05%, Salicylic Acid IP 6%,20gm Tube
18.	169	1387	Clindamycin Gel- Each tube to contain: Clindamycin (As Clindamycin Phosphate) 1%, Packing-10 to 20gm Tube
19.	169	1394	Fluocinolone Lotion, Each Vial to contain: Fluocinolone Acetonide 0.01% w/v,15ml to30ml Vial
20.	169	1428	Clotrimazole + Beclomethasone Dipropionate Lotion- Each Bottle to contain: Clotrimazole 1% w/w, Beclomethasone Dipropionate 0.025% w/v Base, 15ml to 30ml Bottle
21.	169	1492	Item Name: Human Epidermal Growth Factor Gel-Each gm to contain:150µg of recombinant Human Epidermal Growth Factor Gel, 7.5gm Tube and Description: Recombinant Human Epidermal Growth Factor Gel Presentation: 7.5 gm. Route of Administration: For External Use only, Composition: Each gram contains: Purified Bulk of rh-Epidermal Growth Factor-150 µg, Sodium Methylparaben IP-1.8mg
22.	169	1494	Lactobacillus Tab/Cap-EachTab/Cap to contain: 1billion C.F.U of Lactobacillus Rhamnosus GR-1, Lactobacillus Reuteri RC-14
23.	169	1578	Alfuzosin SR/PR/CR/ER/DR/TR: Tab/Cap- Each SR/PR/CR/ER/DR/TR, Tab/Cap to contain: Alfuzosin 10mg

स. ए. आ. इ.  
ESIC

24.	169	1616	Mometasone+Salicylic Acid Oint- Each Tube to contain: Mometasone Furoate 0.1 %, Salicylic Acid 5%,5gm Tube
25.	169	1635	Calcium Syp-Each 5ml to contain: Calcium Lactobionate 1.50 gms (Equivalent 0.87g Of Calcium Gluconate), Calcium Gluconate 0.25g, Cholecalciferol (Vitamin D3) – 200 IU, Cyanocobalamin – 2.5 mcg, Magnesium Chloride –21.25 mg (Equivalent To 2.5mcg Of Elemental Magnesium), Flavoured Base-q.s.,120ml Bottle
26.	169	1714	Mometasone Cream- Each tube to contain: Mometasone Furoate 0.1%,15gm Tube
27.	169	1716	Mometasone + Fusidic Cream- Each tube to contain: Mometasone 0.1% & Fusidic Acid 2%,10gm Tube
28.	169	1722	Coal Tar + Salicylic Acid Oint-Each pack to contain: Coal Tar 6%, Salicylic Acid 3%,75gm Pack
29.	169	1725	Drop- Each ml to contain: Peptonised Iron 117.67 mg (equivalent to 20 mg of elemental iron), Protein (As Peptone) 30 mg, Folic Acid IP 200 mcg, Vitamin B12-4 mcg, Palatable base qs,15ml Bottle
30.	169	1785	Mometasone Furoate Soln-Each Bottle to contain: Mometasone Furoate 0.1% w/v.,15ml Bottle
31.	169	1786	Calcitriol Oint-Each gm to contain: Calcitriol 3mcg.,20gm Tube
32.	169	1792	Haematinic Syp- Each 5 ml to contain: Peptonised Iron 176.5 mg (equivalent to 30 mg of elemental Iron), Protein (as Peptone) 100 mg, Folic Acid 200 mcg, Vitamin B12, 2.5 mcg.,100ml Bottle
33.	169	1794	Calcium & Minerals Tab/Cap-Each Tab/Cap to contain: Calcium Carbonate 1000mg from Organic Source (OysterShell)Equivalent to Elemental Calcium 400mg, Heavy Magnesium Oxide 150mg Equivalent to Elemental Magnesium 90mg, Zinc Sulphate Monohydrate 13.75mg Equivalent to Elemental Zinc 5mg, L-Lysine hydrochloride 100mg, Pyridoxine Hydrochloride 1.5mg, Cholecalciferol 200IU
34.	169	1795	Calcium Tab/Cap: Each Tab/Cap to contain: Elemental Calcium 150mg (In the form of Calcium hydroxide & Calcium oxide pretreated with heated algae ), Zinc sulphate monohydrate equivalent to elemental zinc 7.5mg, Calcitriol 0.25 mcg
35.	169	1950	Glycolic Acid-Each Tube to contain: Glycolic Acid 6%,30gm Tube



ए. ए. सी. ई.  
E S I C

36.	169	1961	Anti Oxidant Tab/Cap- Each Tab/Cap to contain: Methyl cobalamin 500mcg, Folic Acid IP 1.5mg, Zinc Sulphate IP 25mg, Chromium Polynicotinate 200mcg, Selenium 65mcg as Sodium Selenite USP Pyridoxine Hcl IP 1.5mg, Inositol 100mg, Alpha Lipoic Acid USP 50mg Each Inner capsule contains: Streptococcus Faecalis T-10JPC 30million Clostridium Butyricum T- A2 million Bacillus Mesentericus T-OAJPC 1million Lactic Acid Bacillus 50million (Lactobacillus Sporogenes)
37.	169	2044	L-Ornithine L-Aspartate Inj-Each Inj to contain: L-Ornithine L-Aspartate 5.0 g, 10ml Amp
38.	169	2046	Sofosbuvir Tab/Cap-Each Tab/Cap to contain: Sofosbuvir 400 mg
39.	169	2047	Calcium Citrate 1000mg, Vit. D3 200 IU, Methylcobalmin 500mcg, Folic Acid 5mg, Pyridoxin IP 10mg Tab/Cap Each Tab/Cap to contain: Calcium citrate 1000 mg, Vit.D3 200 IU, Methylcobalmin 500 mcg, Folic acid 5 mg, Pyridoxin IP 10mg
40.	169	2050	Darbepoetin Alfa Inj- Each PFS to contain: Darbepoetin Alfa 40 mcg/0.4ml
41.	169	2105	Mupirocin+Beclomethasone-Each Tube to contain: Mupirocin USP 2% w/w, Beclomethasone Dipropionate IP 0.025% w/w, Water soluble base q.s, 5gm Tube
42.	169	2107	Calcium Syrup- Each 5ml to contain: Calcium Lactobionate U.S.P. (Eqv. to 35mg of Calcium)- 700mg Iodised Peptone (Eqv. to 33mcg of Iodine)-0.32mg Magnesium Chloride I.P. (Eqv. to 0.8mg of Magnesium) - 6.66mg Manganese Sulphate B.P. (Eqv. to 0.33mg of Manganese) - 1.33mg Sodium Metavanadate 0.22mg Zinc Sulphate I.P. (Eqv. to 2.5 Mg of Zinc) 10.7mg Pyridoxine Hydrochloride I.P. 0.5mg Nicotinamide I.P. 7.5mg Palatable Base Q.S., 100ml Bottle
43.	169	2108	Ferrous Ascorbate Tab/Cap-Each Film Coated Tab/Cap to contain: Ferrous Ascorbate Equivalent to Elemental Iron 100 mg, Folic Acid 1.1mg, Methylcobalamin 1.5 mg, Zinc Sulphate Monohydrate Equivalent To Elemental Zinc 22.5 mg

म.प्र.सी.सि.  
ESIC

44.	169	2109	Mecobalamin Inj-Each 2ml Amp to contain: Mecobalamin 1500mcg, Pyridoxine Hydrochloride 100mg, Nicotinamide 100mg, Benzyl Alcohol IP 2% v/v, 2ml Amp
45.	169	2110	Calcium + Vitamin Tab/Cap- Each Tab/Cap to contain: Calcium Carbonate 500mg, Calcitriol IP 0.25mcg, Mecobalamin 1500mcg, Eicosapentaenoic Acid 90mg, Docosahexaenoic Acid 60mg, Folic Acid 400mcg, Disodium Tetraborate Eq. To Elemental Boron 1.5mg
46.	169	2111	Calcium + Cholecalciferol Tab/Cap: Each hard gelatin Tab/Cap to contain: Calcium 300mg ( In the form of Calcium hydroxide & Calcium oxide pretreated with heated algae) Cholecalciferol IP 1000 IU
47.	169	2114	Multivitamin Tab/Cap, Each Soft Gelatin Tab/Cap to contain: Ginseng Dry Extract 43.5 mg, Niacinamide 25 mg, Vitamin B6 1 mg, Mecobalamin 500 mcg, Vitamin D3 200 IU, Folic Acid 0.15 mg, Dibasic Calcium Phosphate Eq. to Elemental Calcium 75 mg and Elemental Phosphorous 58 mg, Ferrous Fumarate 30 mg, Zinc Sulphate Monohydrate 10 mg, Magnesium Sulphate Eq. to Elemental Magnesium 3 mg, Manganese Sulphate Eq. to Elemental Manganese 0.5 mg, Copper Sulphate Pentahydrate Eq. To Elemental Copper 0.5 mg, Potassium Iodide Eq. to Elemental Iodine 0.1 mg, Potassium Sulphate Eq. to Elemental Potassium 2 mg
48.	169	2405	Eberconazole Cream-Each Tube to contain: Eberconazole 1% w/w in a Cream Base ,15gm Tube
49.	169	2407	Azelaic Acid Oint/Cream: Each Tube to contain :Azelaic Acid 20%,15gm Tube
50.	169	2410	Kojic Acid Gel: Each Tube to contain: Kojic Acid 2%,15gm Tube
51.	169	2413	Vitamin B12 Inj-Each Vial/Amp to contain- Cyanocobalamin 1000mcg
52.	169	2414	Surgical Spirit: Each Bottle to contain: Surgical Spirit, 1 Litre Bottle





ए. ए. सी. ई. सी.  
E S I C

53.	169	2415	Povidone Iodine Soln.-Each Bottle to contain: Povidone Iodine 5 %, 500ml Bottle
54.	169	2416	Povidone Iodine Scrub-Each Bottle to contain: Povidone Iodine 7.5% w/v Scrub, 500ml Bottle
55.	169	2472	Cholecalciferol Inj-Each ml to contain: Cholecalciferol 600000 (15mg),1ml Vial/Amp
56.	169	2473	Cholecalciferol Drops-Each ml to contain: Cholecalciferol 400IU/Cholecalciferol Nano 400IU, 15ml Bottle
57.	169	2745	Adapalene +Benzoyl Peroxide Gel-Each Tube to contain: Adapalene B.P 0.1% w/w Hydrous Benzoyl Peroxide I.P. equivalent to Anhydrous Benzoyl Peroxide 2.5 % w/w In an aqueous gel base q.s. With Glycerol and Acrylate copolymer,15 to 20gm Gel
58.	169	2747	Each capsule contains: Bacillus mesentericus TO-A JPC 1 Million, Lactobacillus sporogenes 50 Million
59.	169	2748	Each sachet(0.5g) contains: Bacillus mesentericus TO-A JPC 1 Million, Lactobacillus sporogenes 50 Million
60.	169	2751	Calcium Acetate Tab/cap: Each Tab/cap to contain Calcium Acetate 667mg
61.	169	2752	Each film coated tablet contains: Calcium Aspartate 1120mg Magnesium Hydroxide 180mg Vitamin D3 1000IU
62.	169	2754	Clotrimazole+Selenium Sulfide suspension: contains Clotrimazole IP 1% w/v + Selenium Sulfide USP 2.5% w/v,75ml bottle
63.	169	2755	Desidustat Tab/Cap: Each Tab/Cap to contain Desidustat 25mg.
64.	169	2756	Desidustat Tab/Cap: Each Tab/Cap to contain Desidustat 50 mg.
65.	169	2758	Diperoxochloric Acid Topical Solution Pack, 30ml Each Pack contains: Bottle-A: Each ml contains: Diperoxochloric Acid 1.16mg,7.5ml, Bottle-B: Sterile Sodium Chloride Solution 0.9% w/v,22.5ml



ए. ए. सी. ई. सि.  
E S I C

66.	169	2759	Multivitamin Infusion 10ml: Each ml contains: Vitamin A 1100 IU,(as Vitamin A Concentrate Oily form) IP, Cholecalciferol IP 100 IU, Tocopheryl acetate IP 0.5 mg, Nicotinamide IP 10 mg, Riboflavin Sodium Phosphate IP 1.4 mg, Pyridoxine Hydrochloride IP 1.65 mg, Thiamine Hydrochloride IP 5 mg, Ascorbic acid IP 50 mg, L-Cysteine Hydrochloride USP 0.2 mg, Benzyl Alcohol (As preservative) IP 1% v/v, Water for injections IP q.s.
67.	169	2760	Finerenone tab contains: Finerenone micronised 10mg
68.	169	2761	Fluconazole+Azithromycin+Secnidazole kit contain: Fluconazole 150 mg+ Azithromycin 1000mg+Secnidazole 1000 mg
69.	169	2763	IXEKIZUMAB injection: Each vial/amp/PFS to contain IXEKIZUMAB 80mg
70.	169	2765	Lidocaine/Lignocain+ Metronidazole +Sucralfate Cream: - Composition: Lidocaine/Lignocain (4% w/w) + Metronidazole (1% w/w) + Sucralfate (7% w/w) cream 20 gm
71.	169	2767	Mometasone Furoate Monohydrate 50mcg Nasal Spray,100 to 150 metered actualtion/spray/dose
72.	169	2768	Lidocaine+Nifedipine ointment: Composition Lidocaine (1.5% w/w) + Nifedipine (0.3% w/w),30gm
73.	169	2770	Silodosin+Dutasteride Tab/Cap: Each Tab/Cap to contain Silodosin 8mg+Dutasteride 0.5mg
74.	169	2771	Solifenacin Tab/Cap: Each Tab/Cap to contain Solifenacin Succinate 5mg
75.	169	2772	Sucroferric Oxyhydroxide Chewable Tablets: Each Tablet to contain Sucroferric Oxyhydroxide (2500mg) equivalent to Iron 500 mg
76.	169	2773	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 20mg
77.	169	2774	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 10mg



ए. ए. सी. आई.  
ESIC

78.	169	2777	Vitamin A Tab/Cap: Each tab/Cap to contain Vitamin A 25000 IU
79.	169	2780	Zinc Acetate Tab/Cap: Each Tab/Cap to contain Zinc Acetate 50mg
80.	169	2782	METHYLCOBALAMIN NASAL SPRAY 250 MCG/SPRAY For nasal use only 2.3 ml (46 SPRAY) Each 0.1ml contains: (2 SPRAYS) Methylcobalamin IP 500 mcg
81.	169	117a	Clotrimazole Vaginal Tab/Cap-Each Tab/Cap to contain: Clotrimazole 200mg With Applicator
82.	169	1265a	Antiseptic Liquid-Each Bottle to contain: Chloroxylenol 4.8% w/v, Terpeneol 9.0% v/v, Alcohol Absolute (Denatured ) 13.10% v/v, 500ml Bottle
83.	169	1299a	Cholecalciferol Cap/Tab-Each Cap/Tab to contain: Vit. D3 60,000 IU
84.	169	1299b	Cholecalciferol Syp- Each 5ml to contain: Vitamin D3 60,000 IU/Vitamin D3 60,000 IU Nano, 5ml Bottle

क. स. बी. नि.  
ESIC

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Morepen Laboratories Limited	107	Disodium Hydrogen Citrate Liquid- Each 5ml to contain: Disodium Hydrogen Citrate 1.25gm.,100ml Bottle	1ml	ALKAPEN	100ml Bottle	0.11/1ml	Paise Eleven Only	L-1
169	TORQUE PHARMACEUTICALS PVT LTD	107	Disodium Hydrogen Citrate Liquid- Each 5ml to contain: Disodium Hydrogen Citrate 1.25gm.,100ml Bottle	1ml	ALKATOR	100ml Bottle	0.20/1ml	Paise Twenty Only	L-2
169	Wings Biotech LLP	107	Disodium Hydrogen Citrate Liquid- Each 5 ml to contain: Disodium Hydrogen Citrate1.25gm., 100ml Bottle	1ml	CITRALWIN	100ml Bottle	0.23/1ml	Paise Twenty Three Only	L-3
169	MICRON PHARMACEUTICALS	122	Pheniramine Symp- Each 5ml to contain: Pheniramine Maleate 15mg.,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.12/1ml	Paise Twelve Only	L-1
169	Jyoti Capsulations Private Limited	266	VITAMIN A & D Tab/ Cap- Each Tab/ Cap to contain : Vitamin-A 6000 IU, Vitamin-D 1000 IU	1 Tab/Cap	Same as in Item	10 Cap	0.90/1 Cap	Paise Ninety Only	L-1
169	UNICURE INDIA LTD	267	Ferrous Sulphate Tab/Cap-Each Tab/Cap to contain: Ferrous Sulphate 200mg	1 Tab/Cap	Same as in Item	10 Tab	0.94/1 Tab	Paise Ninety Four Only	L-1
169	ZIM LABORATORIES LIMITED	268	Iron & Folic Acid SR Tab/Cap- Each SR Tab/Cap to contain: Ferrous Sulphate 150mg. (in S.R. form), Folic acid 0.5mg	1 Tab/Cap	FOLRON	10 Cap	0.66/1 Cap	Paise Sixty Six Only	L-1
169	Hindustan Laboratories Limited	268	Iron & Folic Acid SR Tab/Cap-Each SR Tab/cap to contain: Ferrous Sulphate 150mg. (in S.R. form), Folic acid 0.5mg	1 Tab/Cap	FERROCID	10 Cap	0.92/1 Cap	Paise Ninety Two Only	L-2
169	Wings Biotech LLP	411	Calamine Lotion- Each Bottle to contain: Calamine IP 15% w/v, Zinc Oxide IP 5% w/v, Bentonite IP 3% w/v, Sodium Citrate IP 0.05% w/v, Glycerin IP 5% w/v , lotion,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.19/1ml	Paise Nineteen Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Nanz Medscience Pharma Pvt. Ltd.	411	Calamine Lotion- Each Bottle to contain: Calamine IP 15% w/v, Zinc Oxide IP 5% w/v, Bentonite IP 3% w/v, Sodium Citrate IP 0.05% w/v, Glycerin IP 5% w/v , lotion,100ml Bottle	1ml	Same as in Item	100ml Bottle	0.23/1ml	Paise Twenty Three Only	L-2
169	ZIM LABORATORIES LIMITED	450	Vitamin Tab/Cap- Each Tab/Cap. To contain: Thiamine 10mg., Riboflavin 8mg., Pyridoxine 3mg., Vit.B125mcg., Niacinamide 50mg., Calcium Pantothenate 15mg., FolicAcid1mg., Ascorbic Acid 125mg.	1 Tab/Cap	ZIM VITAMIN CAPSULES	10 Cap	1.38/1 Cap	Rupee One Paise Thirty Eight Only	L-1
169	Hindustan Laboratories Limited	484	Povidone Iodine Dressing- Containing: Povidone Iodine 10% sterile dressing, Box of 20 dressings.	1 Piece	HIODINE-DRESSING	20 Pouches	29.6/1 Piece	Rupees Twenty Nine Paise Sixty Only	L-1
169	MICRON PHARMACEUTICALS	519	Fluocinolone Oint-Each Tube to contain: Fluocinolone Acetonide 0.1%, Methyl Paraben 0.15%, Propyl Paraben 0.05%,15gm Tube	1gm	Same as in Item	15gm Tube	1.98/1gm	Rupee One Paise Ninety Eight Only	L-1
169	Med Manor Organics Pvt. Ltd.	519	Fluocinolone Oint-Each Tube to contain: Fluocinolone Acetonide 0.1%, Methyl Paraben 0.15%, Propyl Paraben 0.05%,15gm, Tube	1gm	FLUCINOR	15gm Tube	2.40/1gm	Rupees Two Paise Forty Only	L-2
169	Hindustan Laboratories Limited	519	Fluocinolone Oint-Each Tube to contain: Fluocinolone Acetonide 0.1%, Methyl Paraben 0.15%, Propyl Paraben 0.05%, 15gm Tube	1gm	HICTONE OINTMENT	15gm Tube	2.43/1gm	Rupees Two Paise Forty Three Only	L-3
169	Hindustan Laboratories Limited	559	Coal Tar + Salicylic Acid Soln/Lotion- Each Bottle to contain: Coal Tar Topical Sol. 4.25%, Salicylic Acid I.P. Sol. 2%, 60ml Bottle	1ml	KOLTAR	60ml Bottle	2.42/1ml	Rupees Two Paise Forty Two Only	L-1

ESIC

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Nanz Medscience Pharma Pvt. Ltd.	1246	Gamma Benzene Hexachloride Lotion- Each Bottle to Contain: Gamma Benzene Hexachloride 1%, 500ml Bottle	1 ml	LINDANE LOTION USP	500ml Bottle	0.21/1ml	Paise Twenty One Only	L-1
169	MICRON PHARMACEUTICALS	1246	Gamma Benzene Hexachloride Lotion- Each Bottle to Contain: Gamma Benzene Hexachloride 1%,500ml Bottle	1ml	Same as in Item	500ml Bottle	0.25/1ml	Paise Twenty Five Only	L-2
169	Wings Biotech LLP	1246	Gamma Benzene Hexachloride Lotion- Each Bottle to Contain: Gamma Benzene Hexachloride 1%, 500 ml Bottle	1ml	GAMAZENE	100ml Bottle	0.26/1ml	Paise Twenty Six Only	L-3
169	ZIM LABORATORIES LIMITED	1295	Iron TR Tab/Cap- Each TR Tab/cap to contain: Ferrous Fumarate 200mg., Cyanocobalamin 15mcg., Folic Acid 1.5mg	1 Tab/Cap	CALHEM	10 Cap	0.78/1 Cap	Paise Seventy Eight Only	L-1
169	Hindustan Laboratories Limited	1295	Iron TR Tab/Cap-Each TR Tab/cap to contain: Ferrous Fumarate 200mg., Cyanocobalamin 15mcg., Folic Acid 1.5mg.	1 Tab/Cap	FERROFOLA-12	10 Cap	0.85/1 Cap	Paise Eighty Five Only	L-2
169	Morepen Laboratories Limited	1297	Folic Acid Tab/Cap- Each Tab/Cap to contain: Folic Acid 5 mg.	1 Tab/Cap	FOLY-ACT	10 Tab	0.24/1 Tab	Paise Twenty Four Only	L-1
169	Zydus Healthcare Limited	1297	Folic Acid Tab/Cap- Each Tab/Cap to contain: Folic Acid 5 mg.	1 Tab/Cap	FOL - 5	30 Tab	0.26/1 Tab	Paise Twenty Six Only	L-2
169	Overseas Health Care Private Limited	1297	Folic Acid Tab/Cap-Each Tab/Cap to contain: Folic Acid 5 mg.	1 Tab/Cap	GOODVIT	10 Tab	0.54/1 Tab	Paise Fifty Four Only	L-3
169	Tirupati Medicare Ltd.	1299	Cholecalciferol Granules, Each gm to contain: Vit. D3 60,000 IU,1gm Sachet	1 Sachet	N-D3	1gm Sachet	2.77/1 Sachet	Rupees Two Paise Seventy Seven Only	L-1 (50% of Order Quantity)

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Brawn Laboratories Limited	1299	Cholecalciferol Granules, Each gm to contain: Vit. D3 60,000 IU,1gm Sachet	1 Sachet	CIFROL Sachet	1gm Sachet	2.77/1 Sachet	Rupees Two Paise Seventy Seven Only	L-1 (50% of Order Quantity)
169	MICRON PHARMACEUTICALS	1299	Cholecalciferol Granules-Each gm to contain: Vit. D3 60,000 IU,1gm Sachet	1 Sachet	MCIROL	1gm Sachet	2.88/1 Sachet	Rupees Two Paise Eighty Eight Only	L-2
169	Hindustan Laboratories Limited	1299	Cholecalciferol Granules, Each gm to contain: Vit. D3 60,000 IU,1gm Sachet	1 Sachet	HIVIT D3 POWDER	1gm Sachet	3.05/1 Sachet	Rupees Three Paise Five Only	L-3
169	ZIM LABORATORIES LIMITED	1307	Mutivitamin+Zinc Cap/Tab-Each Cap/Tab to contain: Zinc Sulfate Monohydrate 61.8mg. (eqv. to 22.5mg. Of elemental Zinc). Vit. B1-10mg., Vit. B6-2mg., Vit.B12-5mcg., Ca. Pantothenate 12.5mg., Vit. E Acetate 15mg., Vit. C 150mg., Nicotinamide 50mg. And Vit. B2-10mg.	1 Tab/Cap	ZIM MULTIVITAMIN CAPSULES	10 Cap	1.11/1 Cap	Rupee One Paise Eleven Only	L-1
169	Hindustan Laboratories Limited	1307	Mutivitamin+Zinc Cap/Tab-Each Cap/Tab to contain: Zinc Sulfate Monohydrate 61.8mg. (eqv. to 22.5mg. Of elemental Zinc). Vit. B1-10mg., Vit. B6-2mg., Vit.B12-5mcg., Ca. Pantothenate 12.5mg., Vit. E Acetate 15mg., Vit. C 150mg., Nicotinamide 50mg. And Vit. B2-10mg.	1 Tab/Cap	HIVITAL PLUS CAPSULE	30 Cap	1.35/1 Cap	Rupee One Paise Thirty Five Only	L-2

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Tablets (India) Limited	1315	Amino Acid + Vitamin Cap/Tab-Each Cap/Tab to contain: L-Leucine 18.3mg.,L-Isoleucine 5.9mg.,L-LysineHydrochloride25.0mg.,L-Phenylalanine5.0mg.,L-Valine6.7mg.,L-Tryptophan5.0mg.,DL-Methionine18.4mg.,5-Hydroxy Anthranilic Acid Hydrochloride 0.2mg., Vit. A concentrate 2500IU,Vit D3 200IU, Thiamine Mono nitrate 5.0mg., Vit. B2 3.0mg. Nicotinamide 25mg.,Vit.B6 1.5mg.,Folic Acid 0.75mg.,Calcium Pantothenate IP 5.0mg.,Vit.B12 2.5mcg.,Vit.C 40.0mg., Vit. E acetate 7.5 IU, L-Threonine 4.2 mg.	1 Tab/Cap	Astymin Forte	10 Cap	6.12/1 Cap	Rupees Six Paise Twelve Only	L-1
169	HAB Pharmaceuticals & Research Ltd	1364	Salicylic Acid+ Betamethasone Oint-Each Tube to contain: Betamethasone IP 0.05%, Salicylic Acid IP 6%,20gm Tube	1gm	KILIBET-S-6	20gm Tube	6.35/1gm	Rupees Six Paise Thirty Five Only	L-1
169	Nanz Medscience Pharma Pvt. Ltd.	1387	Clindamycin Gel- Each tube to contain: Clindamycin (As Clindamycin Phosphate) 1%, Packing-10 to 20gm Tube	1gm	Same as in Item	20gm Tube	0.57/1gm	Paise Fifty Seven Only	L-1
169	MICRON PHARMACEUTICALS	1387	Clindamycin Gel-Each tube to contain: Clindamycin (As Clindamycin Phosphate) 1%, Packing-10 to 20gm Tube	1gm	Same as in Item	20gm Tube	0.60/1gm	Paise Sixty Only	L-2
169	Wings Biotech LLP	1387	Clindamycin Gel- Each tube to contain: Clindamycin (As Clindamycin Phosphate) 1%, Packing-10 to 20gm Tube	1gm	Same as in Item	20gm Tube	0.62/1gm	Paise Sixty Two Only	L-3

**ESIC**



**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Glenmark Pharmaceuticals Limited	1394	Fluocinolone Lotion, Each Vial to contain: Fluocinolone Acetonide 0.01% w/v,15ml to 30ml Vial	1ml	FLUCORT SKIN LOTION	30ml Bottle	0.87/1ml	Paise Eighty Seven Only	L-1 (50% of Order Quantity)
169	Hindustan Laboratories Limited	1394	Fluocinolone Lotion-Each Vial to contain: Fluocinolone Acetonide 0.01% w/v, 15ml to 30ml Vial	1ml	HICTONE LOTION	30ml Bottle	0.87/1ml	Paise Eighty Seven Only	L-1 (50% of Order Quantity, Class-I Local Supplier)
169	UNICURE INDIA LTD	1394	Fluocinolone Lotion-Each Vial to contain: Fluocinolone Acetonide 0.01% w/v,15ml Vial	1ml	Same as in Item	15ml Bottle	1.64/1ml	Rupee One Paise Sixty Four Only	L-3
169	Hindustan Laboratories Limited	1428	Clotrimazole + Beclomethasone Dipropionate Lotion- Each Bottle to contain: Clotrimazole 1% w/w, Beclomethasone Dipropionate 0.025% w/v Base, 15ml to 30ml Bottle	1ml	CLORIMAZ-B	30ml Bottle	0.73/1ml	Paise Seventy Three Only	L-1
169	Nanz Medscience Pharma Pvt. Ltd.	1428	Clotrimazole + Beclomethasone Dipropionate Lotion- Each Bottle to contain: Clotrimazole 1% w/w, Beclomethasone Dipropionate 0.025% w/v Base, 15ml to 30ml Bottle	1ml	Clotrex-B Lotion	15ml Bottle	0.77/1ml	Paise Seventy Seven Only	L-2
169	Med Manor Organics Pvt. Ltd.	1428	Clotrimazole + Beclomethasone Dipropionate Lotion- Each Bottle to contain: Clotrimazole 1% w/w, Beclomethasone Dipropionate 0.025% w/v Base,15ml Bottle	1ml	C BEST-C LOTION	15ml Bottle	0.84/1ml	Paise Eighty Four Only	L-3

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Bharat Biotech International Limited.	1492	Item Name: Human Epidermal Growth Factor Gel-Each gm to contain:150µg of recombinant Human Epidermal Growth Factor Gel, 7.5gm Tube and Description: Recombinant Human Epidermal Growth Factor Gel Presentation: 7.5 gm. Route of Administration: For External Use only, Composition: Each gram contains: Purified Bulk of rh-Epidermal Growth Factor-150 µg, Sodium Methylparaben IP-1.8mg	1gm	REGEN-D 150	7.5gm Tube	111.86666/1gm	Rupees One Hundred Eleven Paise Eighty Seven Only	L-1
169	Tablets (India) Limited	1494	Lactobacillus Tab/Cap-Each Tab/Cap to contain: 1billion C.F.U of Lactobacillus Rhamnosus GR-1, Lactobacillus Reuteri RC-14	1 Tab/Cap	Ecoflora	10 Cap	42.84/1 Cap	Rupees Forty Two Paise Eighty Four Only	L-1
169	Cipla Ltd.	1578	Alfuzosin SR/PR/CR/ER/DR/TR: Tab/Cap-Each SR/PR/CR/ER/DR/TR, Tab/Cap to contain: Alfuzosin 10mg	1 Tab/Cap	ALFUSIN	15 Tab	2.27/1 Tab	Rupees Two Paise Twenty Seven Only	L-1
169	Overseas Health Care Private Limited	1578	Alfuzosin SR/PR/CR/ER/DR/TR: Tab/Cap-Each SR/PR/CR/ER/DR/TR, Tab/Cap to contain: Alfuzosin 10mg	1 Tab/Cap	EFZU	10 Tab	3.06/1 Tab	Rupees Three Paise Six Only	L-2
169	HAB Pharmaceuticals & Research Ltd	1616	Mometasone+Salicylic Acid Oint- Each Tube to contain: Mometasone Furoate 0.1%, Salicylic Acid 5%,5gm Tube	1gm	MOMECON S	5gm Tube	5.32/1gm	Rupees Five Paise Thirty Two Only	L-1
169	UNICURE INDIA LTD	1616	Mometasone+Salicylic Acid Oint-Each Tube to contain: Mometasone Furoate 0.1 %, Salicylic Acid 5%,5gm Tube	1gm	Same as in Item	5gm Tube	6.88/1gm	Rupees Six Paise Eighty Eight Only	L-2
169	Med Manor Organics Pvt. Ltd.	1616	Mometasone+Salicylic Acid Oint- Each Tube to contain: Mometasone Furoate 0.1 %, Salicylic Acid 5%,5gm Tube	1gm	DERMAMED-MS	5gm Tube	7.38/1gm	Rupees Seven Paise Thirty Eight Only	L-3

ESIC

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Raptakos, Brett & Company Limited	1635	Calcium Syp-Each 5ml to contain: Calcium Lactobionate 1.50 gms (Equivalent 0.87g Of Calcium Gluconate), Calcium Gluconate 0.25g, Cholecalciferol (Vitamin D3) – 200 IU, Cyanocobalamin – 2.5 mcg, Magnesium Chloride –21.25 mg (Equivalent To 2.5mcg Of Elemental Magnesium), Flavoured Base-Q.S.,120ml Bottle	1ml	CALCINOL SYRUP	120ml Bottle	0.82/1ml	Paise Eighty Two Only	L-1
169	RIVPRA FORMULATION PVT. LTD,	1714	Mometasone Cream- Each tube to contain: Mometasone Furoate 0.1%,15gm Tube	1gm	Same as in Item	15gm Tube	0.62/1gm	Paise Sixty Two Only	L-1
169	HAB Pharmaceuticals & Research Ltd	1714	Mometasone Cream-Each tube to contain: Mometasone Furoate 0.1%,15gm Tube	1gm	MOMECON	15gm Tube	0.73/1gm	Paise Seventy Three Only	L-2
169	ALPA LABORATORIES LTD	1714	Mometasone Cream-Each tube to contain: Mometasone Furoate 0.1%,15gmTube	1gm	Same as in Item	15gm Tube	0.74/1gm	Paise Seventy Four Only	L-3
169	HAB Pharmaceuticals & Research Ltd	1716	Mometasone + Fusidic Cream- Each tube to contain: Mometasone 0.1% & Fusidic Acid 2%,10gm Tube	1gm	FUSISIGN M	10gm Tube	2.14/1gm	Rupees Two Paise Fourteen Only	L-1
169	Med Manor Organics Pvt. Ltd.	1716	Mometasone + Fusidic Cream- Each tube to contain: Mometasone 0.1% & Fusidic Acid 2%,10gm Tube	1gm	Dermamed - MF Cream	10gm Tube	2.34/1gm	Rupees Two Paise Thirty Four Only	L-2
169	UNICURE INDIA LTD	1716	Mometasone + Fusidic Cream- Each tube to contain: Mometasone 0.1% & Fusidic Acid 2%,10gm Tube	1gm	Same as in Item	10gm Tube	2.64/1gm	Rupees Two Paise Sixty Four Only	L-3
169	Med Manor Organics Pvt. Ltd.	1722	Coal Tar + Salicylic Acid Oint-Each pack to contain: Coal Tar 6%, Salicylic Acid 3%,75gm Pack	1gm	TARSALZ	75gm Pack	1.20/1gm	Rupee One Paise Twenty Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	UNICURE INDIA LTD	1722	Coal Tar + Salicylic Acid Oint-Each pack to contain: Coal Tar 6%, Salicylic Acid 3%,75gm Pack	1gm	ASTAR Ointment	75gm Pack	2.24/1gm	Rupees Two Paise Twenty Four Only	L-2
169	Raptakos, Brett & Company Limited	1725	Drop- Each ml to contain: Peptonised Iron 117.67 mg (equivalent to 20 mg of elemental iron), Protein (As Peptone) 30 mg, Folic Acid IP 200 mcg, Vitamin B12-4 mcg, Palatable base qs,15ml Bottle	1ml	HEPATOLOBIN E DROPS	15ml Bottle	3.67/1ml	Rupees Three Paise Sixty Seven Only	L-1
169	Glenmark Pharmaceuticals Limited	1785	Mometasone Furoate Soln-Each Bottle to contain: Mometasone Furoate 0.1% w/v.,15ml Bottle	1ml	MOMATE LOTION	15ml Bottle	1.82/1ml	Rupee One Paise Eighty Two Only	L-1
169	Hindustan Laboratories Limited	1785	Mometasone Furoate Soln-Each Bottle to contain: Mometasone Furoate 0.1% w/v., 15ml Bottle	1ml	HICOMINE LOTION	15ml Bottle	2.43/1ml	Rupees Two Paise Forty Three Only	L-2
169	Med Manor Organics Pvt. Ltd.	1785	Mometasone Furoate Soln-Each Bottle to contain: Mometasone Furoate 0.1% w/v.,15ml Bottle	1ml	Dermamed Lotion	15ml Bottle	2.82/1ml	Rupees Two Paise Eighty Two Only	L-3
169	Med Manor Organics Pvt. Ltd.	1786	Calcitriol Oint-Each gm to contain: Calcitriol 3mcg.,20gm Tube	1gm	Psoralys	20gm Tube	6.30/1gm	Rupees Six Paise Thirty Only	L-1
169	Raptakos, Brett & Company Limited	1792	Haematinic Syp- Each 5 ml to contain: Peptonised Iron 176.5 mg (equivalent to 30 mg of elemental Iron), Protein (as Peptone) 100 mg, Folic Acid 200 mcg, Vitamin B12 2.5 mcg.,100ml Bottle	1ml	HEPATOLOBIN E MIKROS	100ml Bottle	1.07/1ml	Rupee One Paise Seven Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Tablets (India) Limited	1794	Calcium & Minerals Tab/Cap-Each Tab/Cap to contain: Calcium Carbonate 1000mg from Organic Source (OysterShell)Equivalent to Elemental Calcium 400mg, Heavy Magnesium Oxide 150mg Equivalent to Elemental Magnesium 90mg, Zinc Sulphate Monohydrate 13.75mg Equivalent to Elemental Zinc 5mg, L-Lysine hydrochloride 100mg, Pyridoxine Hydrochloride 1.5mg, Cholecalciferol 200IU	1 Tab/Cap	Aminocal	15 Tab	3.86/1 Tab	Rupees Three Paise Eighty Six Only	L-1
169	USV Private Limited	1795	Calcium Tab/Cap: Each Tab/Cap to contain: Elemental Calcium 150mg ( In the form of Calcium hydroxide & Calcium oxide pretreated with heated algae ), Zinc sulphate monohydrate equivalent to elemental zinc 7.5mg, Calcitriol 0.25 mcg	1 Tab/Cap	Triple A Cal - OS	10 Cap	9.57/1 Cap	Rupees Nine Paise Fifty Seven Only	L-1
169	MICRO LABS LTD	1950	Glycolic Acid-Each Tube to contain: Glycolic Acid 6%,30gm Tube	1gm	GLYCO 6	30gm Tube	2.74/1gm	Rupees Two Paise Seventy Four Only	L-1
169	Tablets (India) Limited	1961	Anti Oxidant Tab/Cap- EachTab/Cap to contain: Methyl cobalamin 500mcg, Folic Acid IP1.5mg, Zinc Sulphate IP 25mg, Chromium Polynicotinate 200mcg, Selenium 65mcg as Sodium Selenite USP Pyridoxine Hcl IP 1.5mg, Inositol 100mg, Alpha Lipoic Acid USP 50mg Each Inner capsule contains: Streptococcus Faecalis T-10JPC 30million Clostridium Butyricum T- A2 million Bacillus Mesentericus T-OAJPC 1million Lactic Acid Bacillus 50million (Lactobacillus Sporogenes)	1 Tab/Cap	Nugica	10 Cap	15.38/1 Cap	Rupees Fifteen Paise Thirty Eight Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Zuventus Healthcare Limited	2044	L-Ornithine L-Aspartate Inj-Each Inj to contain: L-Ornithine L-Aspartate 5.0 g,10ml Amp	1ml	Lornit	10ml Ampoule	7.50/1ml	Rupees Seven Paise Fifty Only	L-1
169	MICRON PHARMACEUTICALS	2046	Sofosbuvir Tab/Cap-Each Tab/Cap to contain: Sofosbuvir 400 mg	1 Tab/Cap	Same as in Item	28 Tab	74.70/1 Tab	Rupees Seventy Four Paise Seventy Only	L-1
169	Indoco Remedies Ltd.	2047	Calcium Citrate 1000mg, Vit. D3 200 IU, Methylcobalmin 500mcg, Folic Acid 5mg, Pyridoxin IP 10mg Tab/Cap Each Tab/Cap to contain: Calcium citrate 1000 mg, Vit.D3 200 IU, Methylcobalmin 500 mcg, Folic acid 5 mg, Pyridoxin IP 10mg	1 Tab/Cap	Methycal Tab	15 Tab	7.70/1 Tab	Rupees Seven Paise Seventy Only	L-1
169	Dr. Reddy's Laboratories Limited	2050	Darbepoetin Alfa Inj- Each PFS to contain: Darbepoetin Alfa 40 mcg/0.4ml	1 PFS	Cresp 40	1 PFS	469/1 PFS	Rupees Four Hundred Sixty Nine Only	L-1
169	HAB Pharmaceuticals & Research Ltd	2105	Mupirocin+Beclomethasone-Each Tube to contain: Mupirocin USP 2% w/w, Beclomethasone Dipropionate IP 0.025% w/w, Water soluble base q.s,5gm Tube	1gm	INFECTO B	5gm Tube	7.90/1gm	Rupees Seven Paise Ninety Only	L-1
169	Hindustan Laboratories Limited	2105	Mupirocin+Beclomethasone-Each Tube to contain: Mupirocin USP 2% w/w, Beclomethasone Dipropionate IP 0.025% w/w, Water soluble base q.s, 5gm Tube	1gm	HINROCIN-B	5gm Tube	7.91/1gm	Rupees Seven Paise Ninety One Only	L-2
169	Med Manor Organics Pvt. Ltd.	2105	Mupirocin+Beclomethasone-Each Tube to contain: Mupirocin USP 2% w/w, Beclomethasone Dipropionate IP 0.025% w/w, Water soluble base q.s, 5gm Tube	1gm	Mupinor - B	5gm Tube	9.54/1gm	Rupees Nine Paise Fifty Four Only	L-3

**ESIC**

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Raptakos, Brett & Company Limited	2107	Calcium Syp- Each 5ml to contain: Calcium Lactobionate U.S.P. (Eqv. to 35mg of Calcium)- 700mg Iodised Peptone (Eqv. to 33mcg of Iodine)- 0.32mg Magnesium Chloride I.P. (Eqv. to 0.8mg of Magnesium) - 6.66mg Manganese Sulphate B.P. (Eqv. to 0.33mg of Manganese) - 1.33mg Sodium Metavanadate 0.22mg Zinc Sulphate I.P. (Eqv. to 2.5 Mg of Zinc) 10.7mg Pyridoxine Hydrochloride I.P. 0.5mg Nicotinamide I.P. 7.5mg Palatable Base Q.S.,100ml Bottle	1ml	NEOGADINE MIKROS	100ml Bottle	0.95/1ml	Paise Ninety Five Only	L-1
169	Theon Pharmaceuticals Limited	2108	Ferrous Ascorbate Tab/Cap-Each Film Coated Tab/Cap to contain: Ferrous Ascorbate Equivalent to Elemental Iron 100 mg, Folic Acid 1.1mg, Mecobalamin 1.5 mg, Zinc Sulphate Monohydrate Equivalent To Elemental Zinc 22.5 mg	1 Tab/Cap	Same as in Item	10 Tab	3.59/1 Tab	Rupees Three Paise Fifty Nine Only	L-1
169	Emcure Pharmaceuticals Limited	2108	Ferrous Ascorbate Tab/Cap-Each Film Coated Tab/Cap to contain : Ferrous Ascorbate Equivalent To Elemental Iron 100 mg, Folic Acid 1.1 mg , Mecobalamin 1.5 mg, Zinc Sulphate Monohydrate Equivalent To Elemental Zinc 22.5 mg	1 Tab/Cap	Orofer XT Total	10 Tab	4.00/1 Tab	Rupees Four Only	L-2
169	MANKIND PHARMA LIMITED	2109	Mecobalamin Inj-Each 2ml Amp to contain: Mecobalamin 1500mcg, Pyridoxine Hydrochloride 100mg, Nicotinamide 100mg, Benzyl Alcohol IP 2% v/v,2ml Amp	1 Amp	NUROKIND GOLD INJECTION	2ml Ampoule	9.90/1 Amp	Rupees Nine Paise Ninety Only	L-1

DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	MANKIND PHARMA LIMITED	2110	Calcium + Vitamin Tab/Cap- Each Tab/Cap to contain: Calcium Carbonate 500mg, Calcitriol IP 0.25mcg, Mecobalamin 1500mcg, Eicosapentaenoic Acid 90mg, Docosahexaenoic Acid 60mg, Folic Acid 400mcg, Disodium Tetraborate Eq. To Elemental Boron 1.5mg	1 Tab/Cap	MAXICAL GOLD	10 Cap	7.30/1 Cap	Rupees Seven Paise Thirty Only	L-1
169	USV Private Limited	2111	Calcium + Cholecalciferol Tab/Cap: Each hard gelatin Tab/Cap to contain: Calcium 300mg ( In the form of Calcium hydroxide & Calcium oxide pretreated with heated algae) Cholecalciferol IP 1000 IU	1 Tab/Cap	Triple A Cal FD	15 Cap	8.13/1 Cap	Rupees Eight Paise Thirteen Only	L-1
169	MANKIND PHARMA LIMITED	2114	Multivitamin Tab/Cap, Each Soft Gelatin Tab/Cap to contain: Ginseng Dry Extract 43.5 mg, Niacinamide 25 mg, Vitamin B6 1 mg, Mecobalamin 500 mcg, Vitamin D3 200 IU, Folic Acid 0.15 mg, Dibasic Calcium Phosphate Eq. to Elemental Calcium 75 mg and Elemental Phosphorous 58 mg, Ferrous Fumarate 30 mg, Zinc Sulphate Monohydrate 10 mg, Magnesium Sulphate Eq. to Elemental Magnesium 3 mg, Manganese Sulphate Eq. to Elemental Manganese 0.5 mg, Copper Sulphate Pentahydrate Eq. To Elemental Copper 0.5 mg, Potassium Iodide Eq. to Elemental Iodine 0.1 mg, Potassium Sulphate Eq. to Elemental Potassium 2 mg	1 Tab/Cap	NUROSTAR-GOLD RF	10 Cap	4.80/1 Cap	Rupees Four Paise Eighty Only	L-1



**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	UNICURE INDIA LTD	2405	Eberconazole Cream-Each Tube to contain: Eberconazole 1% w/w in a Cream Base ,15gm Tube	1gm	Same as in Item	15gm Tube	3.24/1gm	Rupees Three Paise Twenty Four Only	L-1
169	Signature Phytochemical Industries	2405	Eberconazole Cream- Each Tube to contain: Eberconazole 1% w/w in a Cream Base, 15gm Tube	1gm	EBERSIGN	15gm Tube	3.26/1gm	Rupees Three Paise Twenty Six Only	L-2
169	Med Manor Organics Pvt. Ltd.	2405	Eberconazole Cream-Each Tube to contain: Eberconazole 1% w/w in a Cream Base ,15gm Tube	1gm	Ebermed Cream	15gm Tube	3.48/1gm	Rupees Three Paise Forty Eight Only	L-3
169	MICRO LABS LTD	2407	Azelaic Acid Oint/Cream: Each Tube to contain :Azelaic Acid 20%,15gm Tube	1gm	AZIDERM Cream	15gm Tube	6.53/1gm	Rupees Six Paise Fifty Three Only	L-1
169	HAB Pharmaceuticals & Research Ltd	2407	Azelaic Acid Oint/Cream: Each Tube to contain :Azelaic Acid 20%,15gm Tube	1gm	AZESIGN	15gm Tube	6.99/1gm	Rupees Six Paise Ninety Nine Only	L-2
169	HAB Pharmaceuticals & Research Ltd	2410	Kojic Acid Gel: Each Tube to contain: Kojic Acid 2%,15gm Tube	1gm	E-SCAR LITE	15gm Tube	12.66/1gm	Rupees Twelve Paise Sixty Six Only	L-1
169	ALPA LABORATORIES LTD	2413	Vitamin B12 Inj-Each Vial/Amp to contain-Cyanocobalamin 1000mcg	1 Vial/Amp	Same as in Item	1ml Ampoule	127/1 Amp	Rupees One Hundred Twenty Seven Only	L-1
169	Hindustan Laboratories Limited	2414	Surgical Spirit: Each Bottle to contain: Surgical Spirit, 1 Litre Bottle	1ml	HI-ALCO	1 Litre Bottle	0.35/1ml	Paise Thirty Five Only	L-1
169	Hindustan Laboratories Limited	2415	Povidone Iodine Soln.-Each Bottle to contain: Povidone Iodine 5 %, 500ml Bottle	1ml	HIODINE-5%	500 ml Bottle	0.18/1ml	Paise Eighteen Only	L-1
169	Nanz Medscience Pharma Pvt. Ltd.	2415	Povidone Iodine Soln.- Each Bottle to contain: Povidone Iodine 5%,500ml Bottle	1ml	Povinzan 5% Solution	500ml Bottle	0.22/1ml	Paise Twenty Two Only	L-2
169	Hindustan Laboratories Limited	2416	Povidone Iodine Scrub-Each Bottle to contain: Povidone Iodine 7.5 % w/v Scrub, 500ml Bottle	1ml	HIODINE-7.5%	500ml Bottle	0.27/1ml	Paise Twenty Seven Only	L-1

ESIC

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Nanz Medscience Pharma Pvt. Ltd.	2416	Povidone Iodine Scrub-Each Bottle to contain: Povidone Iodine 7.5% w/v Scrub, 500ml Bottle	1ml	Povinzan 7.5% Scrub	500ml Bottle	0.31/1ml	Paise Thirty One Only	L-2
169	Primus Pharmaceuticals	2472	Cholecalciferol Inj-Each ml to contain: Cholecalciferol 600000 (15mg),1ml Vial/Amp	1 Vial/Amp	PRIMCAL-600000	1ml Ampoule	17.50/1 Amp	Rupees Seventeen Paise Fifty Only	L-1
169	Cadila Pharmaceuticals Limited	2472	Cholecalciferol Inj-Each ml to contain: Cholecalciferol 600000 (15mg),1ml Vial/Amp	1 Vial/Amp	CALCIROL INJECTION	1ml Ampoule	25.69/1 Amp	Rupees Twenty Five Paise Sixty Nine Only	L-2
169	Morepen Laboratories Limited	2473	Cholecalciferol Drops-Each ml to contain: Cholecalciferol 400IU/Cholecalciferol Nano 400IU, 15ml Bottle	1ml	Calciquick D3 KID	15ml Bottle	0.58/1ml	Paise Fifty Eight Only	L-1
169	UNICURE INDIA LTD	2473	Cholecalciferol Drops-Each ml to contain: Cholecalciferol 400IU/Cholecalciferol Nano 400IU, 15ml Bottle	1ml	Same as in Item	15ml Bottle	0.68/1ml	Paise Sixty Eight Only	L-2
169	Pulse Pharmaceuticals Pvt Ltd	2473	Cholecalciferol Drops-Each ml to contain: Cholecalciferol 400IU/Cholecalciferol Nano 400IU, 15ml Bottle	1ml	Deksel Nano Drops Kids	15ml Bottle	6.00/1ml	Rupees Six Only	L-3
169	Glenmark Pharmaceuticals Limited	2745	Adapalene +Benzoyl Peroxide Gel-Each Tube to contain: Adapalene B.P 0.1% w/w Hydrous Benzoyl Peroxide I.P. equivalent to Anhydrous Benzoyl Peroxide 2.5 % w/w In an aqueous gel base q.s. With Glycerol and Acrylate copolymer,15 to 20gm Gel	1gm	DERIVA-BPO GEL	20gm Tube	3.72/1gm	Rupees Three Paise Seventy Two Only	L-1
169	Tablets (India) Limited	2747	Each capsule contains: Bacillus mesentericus TO-A JPC 1 Million, Lactobacillus sporogenes 50 Million	1 Tab/Cap	BioBind Capsule	10 Cap	4.25/1 Cap	Rupees Four Paise Twenty Five Only	L-1

**ESIC**

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Tablets (India) Limited	2748	Each sachet(0.5g) contains: Bacillus mesentericus TO-A JPC 1 Million, Lactobacillus sporogenes 50 Million	1 Sachet	BioBind Sachet	1 Sachet	6.95/1 Sachet	Rupees Six Paise Ninety Five Only	L-1
169	Zydus Lifesciences Limited	2751	Calcium Acetate Tab/cap: Each Tab/cap to contain Calcium Acetate 667mg	1 Tab/Cap	PHOSTAT	10 Tab	0.55/1 Tab	Paise Fifty Five Only	L-1
169	MICRON PHARMACEUTICALS	2751	Calcium Acetate Tab/cap: Each Tab/cap to contain Calcium Acetate 667mg	1 Tab/Cap	Same as in Item	10 Tab	2.70/1 Tab	Rupees Two Paise Seventy Only	L-2
169	Overseas Health Care Private Limited	2752	Each film coated tablet contains: Calcium Aspartate 1120mg Magnesium Hydroxide 180mg Vitamin D3 1000IU	1 Tab/Cap	EZORB D3+	15 Tab	7.92/1 Tab	Rupees Seven Paise Ninety Two Only	L-1
169	Glenmark Pharmaceuticals Limited	2754	Clotrimazole+Selenium Sulfide suspension: contains Clotrimazole IP 1% w/v + Selenium Sulfide USP 2.5% w/v,75ml bottle	1ml	CANDID TV SUSPENSION	75ml Bottle	1.27/1ml	Rupee One Paise Twenty Seven Only	L-1
169	Zydus Lifesciences Limited	2755	Desidustat Tab/Cap: Each Tab/Cap to contain Desidustat 25mg.	1 Tab/Cap	OXEMIA 25	6 Tab	39/1 Tab	Rupees Thirty Nine Only	L-1
169	Zydus Lifesciences Limited	2756	Desidustat Tab/Cap: Each Tab/Cap to contain Desidustat 50 mg.	1 Tab/Cap	OXEMIA 50	6 Tab	75/1 Tab	Rupees Seventy Five Only	L-1
169	Centaur Pharmaceuticals Pvt. Ltd.	2758	Diperoxochloric Acid Topical Solution Pack, 30ml Each Pack contains: Bottle-A: Each ml contains: Diperoxochloric Acid 1.16mg,7.5ml, Bottle-B: Sterile Sodium Chloride Solution 0.9% w/v,22.5ml	1 Pack	WOXheal	30ml Pack	1452/1 Pack	Rupees One Thousand Four Hundred Fifty Two Only	L-1

क.रा.बी.नि.  
ESIC

DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Tablets (India) Limited	2759	Multivitamin Infusion 10ml: Each ml contains: Vitamin A 1100 IU,(as Vitamin A Concentrate Oily form) IP, Cholecalciferol IP 100 IU, Tocopheryl acetate IP 0.5 mg, Nicotinamide IP 10 mg, Riboflavin Sodium Phosphate IP 1.4 mg, Pyridoxine Hydrochloride IP 1.65 mg, Thiamine Hydrochloride IP 5 mg, Ascorbic acid IP 50 mg, L-Cysteine Hydrochloride USP 0.2 mg, Benzyl Alcohol (As preservative) IP 1% v/v, Water for injections IP q.s.	10ml Vial/Amp	Tilvit	10ml Ampoule	32.63/1 Amp	Rupees Thirty Two Paise Sixty Three Only	L-1
169	Bayer Pharmaceuticals Private Limited	2760	Finerenone tab contains: Finerenone micronised 10mg	1 Tab/Cap	Kerendia 10mg (Manufactured by: Bayer AG Germany)	14 Tab	69.64/1 Tab	Rupees Sixty Nine Paise Sixty Four Only	L-1
169	DWD Pharmaceuticals Ltd.	2761	Fluconazole+Azithromycin+Secnidazole kit contain: Fluconazole 150 mg+ Azithromycin 1000mg+Secnidazole 1000 mg	1 Kit	VDM-Kit	1 Combikit of 4 Tab	63.77/1 Kit	Rupees Sixty Three Paise Seventy Seven Only	L-1
169	Eli Lilly and Company (India) Pvt. Ltd	2763	IXEKIZUMAB injection: Each vial/amp/PFS to contain IXEKIZUMAB 80mg	1 Vial/Amp/ PFS	COPELLOR (Ixekizumab) Mfg by: Eli Lilly and Company, Lilly Corporate Centre Indianapolis, Indiana-46285, USA	1 PF Auto injector	19491/1 PFA	Rupees Nineteen Thousand Four Hundred Ninety One Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	DWD Pharmaceuticals Ltd.	2765	Lidocaine/Lignocain+ Metronidazole +Sucralfate Cream: - Composition: Lidocaine/Lignocain (4% w/w) + Metronidazole (1% w/w) + Sucralfate (7% w/w) cream 20 gm	1gm	ESCOT MS CREAM	20gm Tube	1.97/1gm	Rupee One Paise Ninety Seven Only	L-1
169	Biodeal Pharmaceuticals Ltd.	2767	Mometasone Furoate Monohydrate 50mcg Nasal Spray,100 to 150 metered actualtion/spray/dose	1 Metered Actualtion/ Spray/ Dose	Same as in Item	120 Metered Doses	0.39/1 MD	Paise Thirty Nine Only	L-1
169	Cipla Ltd.	2767	Mometasone Furoate Monohydrate 50mcg Nasal Spray,100 to 150 metered actualtion/spray/dose	1 Metered Actualtion/ Spray/ Dose	METASPRAY Nasal spray	100 Metered Doses	0.55/1 MD	Paise Fifty Five Only	L-2
169	HAB Pharmaceuticals & Research Ltd	2767	Mometasone Furoate Monohydrate 50mcg Nasal Spray,100 to 150 metered actualtion/spray/dose	1 Metered Actualtion/ Spray/ Dose	MOMECON Nasal Spray	140 Metered dose	1.25/1 MD	Rupee One Paise Twenty Five Only	L-3
169	DWD Pharmaceuticals Ltd.	2768	Lidocaine+Nifedipine ointment: Composition Lidocaine (1.5% w/w) + Nifedipine (0.3% w/w),30gm	1gm	ESCOT CREAM	30gm Tube	1.10/1gm	Rupee One Paise Ten Only	L-1
169	MASCOT HEALTH SERIES PVT LTD	2770	Silodosin+Dutasteride Tab/Cap: Each Tab/Cap to contain Silodosin 8mg+Dutasteride 0.5mg	1 Tab/Cap	SILDAMAS-D	10 Tab	2.25/1 Tab	Rupees Two Paise Twenty Five Only	L-1
169	Overseas Health Care Private Limited	2770	Silodosin+Dutasteride Tab/Cap: Each Tab/Cap to contain Silodosin 8mg+Dutasteride 0.5mg	1 Tab/Cap	SILOCAP-D	10 Cap	8.40/1 Cap	Rupees Eight Paise Forty Only	L-2
169	Cipla Ltd.	2771	Solifenacin Tab/Cap: Each Tab/Cap to contain Solifenacin Succinate 5mg	1 Tab/Cap	SOLIACT 5	15 Tab	7.33/1 Tab	Rupees Seven Paise Thirty Three Only	L-1
169	Overseas Health Care Private Limited	2771	Solifenacin Tab/Cap: Each Tab/Cap to contain Solifenacin Succinate 5mg	1 Tab/Cap	SOLIDIF 5	10 Tab	21/1 Tab	Rupees Twenty One Only	L-2

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Emcure Pharmaceuticals Limited	2772	Sucroferic Oxyhydroxide Chewable Tablets: Each Tablet to contain Sucroferic Oxyhydroxide (2500mg) equivalent to Iron 500 mg	1 Tab/Cap	Dynulta	6 Tab	45/1 Tab	Rupees Forty Five Only	L-1
169	RIVPRA FORMULATION PVT. LTD.	2773	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 20mg	1 Tab/Cap	TADARIK-20	10 Tab	0.87/1 Tab	Paise Eighty Seven Only	L-1
169	Cipla Ltd.	2773	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 20mg	1 Tab/Cap	PULMOPRES	15 Tab	1.10/1 Tab	Rupee One Paise Ten Only	L-2
169	Macleods Pharmaceuticals Limited	2773	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 20mg	1 Tab/Cap	MEGALIS-20	4 Tab	10.75/1 Tab	Rupees Ten Paise Seventy Five Only	L-3
169	RIVPRA FORMULATION PVT. LTD.	2774	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 10mg	1 Tab/Cap	TADARIK-10	10 Tab	0.75/1 Tab	Paise Seventy Five Only	L-1
169	Macleods Pharmaceuticals Limited	2774	Tadalafil Tab/Cap: Each Tab/Cap to contain Tadalafil 10mg	1 Tab/Cap	MEGALIS-10	4 Tab	8.50/1 Tab	Rupees Eight Paise Fifty Only	L-2
169	Jyoti Capsulations Private Limited	2777	VITAMIN A Tab/ Cap-Each Tab/ Cap to contain: Vitamin-A 25,000 IU	1 Tab/Cap	Same as in Item	10 Cap	0.75/1 Cap	Paise Ninety Three Only	L-1
169	USV Private Limited	2777	Vitamin A Tab/Cap: Each tab/Cap to contain Vitamin A 25000 IU	1 Tab/Cap	Aquasol A CAPSULES	30 Cap	0.93/1 Cap	Paise Seventy Five Only	L-2
169	Zuventus Healthcare Limited	2780	Zinc Acetate Tab/Cap: Each Tab/Cap to contain Zinc Acetate 50mg	1 Tab/Cap	Zinconia - 50	10 Tab	1.60/1 Tab	Rupees Five Paise Seventy Six Only	L-1
169	Troikaa Pharmaceuticals Limited	2782	METHYLCOBALAMIN NASAL SPRAY 250 MCG/SPRAY For nasal use only 2.3 ml (46 SPRAY) Each 0.1ml contains: (2 SPRAYS) Methylcobalamin IP 500 mcg	1 Spray	NASO B12	2.3ML (46 Sprays)	5.76/1 Spray	Rupee One Paise Sixty Only	L-1

**DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027**

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	MICRON PHARMACEUTICALS	117a	Clotrimazole Vaginal Tab/Cap-Each Tab/Cap to contain: Clotrimazole 200mg With Applicator	1 Tab/Cap	Same as in Item	3 Tab	4.50/1 Tab	Rupees Four Paise Ninety Four Only	L-1
169	UNICURE INDIA LTD	117a	Clotrimazole Vaginal Tab/Cap-Each Tab/Cap to contain: Clotrimazole 200mg With Applicator	1 Tab/Cap	Same as in Item	10 Tab	4.94/1 Tab	Rupees Four Paise Fifty Only	L-2
169	HAB Pharmaceuticals & Research Ltd	117a	Clotrimazole Vaginal Tab/Cap-Each Tab/Cap to contain: Clotrimazole 200mg With Applicator	1 Tab/Cap	CLOZOLE V-3	3 Tab	5.20/1 Tab	Rupees Five Paise Twenty Only	L-3
169	Nanz Medscience Pharma Pvt. Ltd.	1265a	Antiseptic Liquid- Each Bottle to contain: Chloroxylenol 4.8% w/v, Terpineol 9.0% v/v, Alcohol Absolute (Denatured) 13.10% v/v, 500ml Bottle	1ml	Extol	500ml Bottle	0.21/1ml	Rupees Two Paise Six Only	L-1
169	Hindustan Laboratories Limited	1265a	Antiseptic Liquid-Each Bottle to contain: Chloroxylenol 4.8% w/v, Terpineol 9.0% v/v, Alcohol Absolute (Denatured ) 13.10% v/v, 500ml Bottle	1ml	HIGERM-OL	500ml Bottle	0.23/1ml	Paise Twenty One Only	L-2
169	RIVPRA FORMULATION PVT. LTD,	1299a	Cholecalciferol Cap/Tab- Each Cap/Tab to contain : Vit. D3 60,000 IU	1 Tab/Cap	Same as in Item	4 Tab	2.06/1 Tab	Paise Twenty Three Only	L-1
169	Overseas Health Care Private Limited	1299a	Cholecalciferol Cap/Tab-Each Cap/Tab to contain : Vit. D3 60,000 IU	1 Tab/Cap	OD3 60K	4 Tab	2.16/1 Tab	Rupees Two Paise Sixteen Only	L-2
169	LOGOS PHARMA	1299a	Cholecalciferol Cap/Tab-Each Cap/Tab to contain : Vit. D3 60,000 IU	1 Tab/Cap	Same as in Item	4 Tab	2.25/1 Tab	Rupees Two Paise Twenty Five Only	L-3
169	Morepen Laboratories Limited	1299b	Cholecalciferol Syp- Each 5ml to contain: Vitamin D3 60,000 IU/Vitamin D3 60,000 IU Nano, 5ml Bottle	1ml	Calciquick- D3 NANO	5ml Bottle	1.69/1ml	Rupees Nine Paise Eighty One Only	L-1
169	Hindustan Laboratories Limited	1299b	Cholecalciferol Syp- Each 5ml to contain: Vitamin D3 60,000 IU/Vitamin D3 60,000 IU Nano, 5ml Bottle	1ml	HIVIT D3 SOLUTION	5ml Bottle	3.60/1ml	Rupee One Paise Sixty Nine Only	L-2

DG-ESIC Central Rate Contract No.169 valid w.e.f 11.12.2025 to 10.12.2027

RC No.	Approved Pharmaceutical Firm	Item No.	Item Name and Description	Unit	Description of Stores Accepted	Packing Offered by firm	Rate/Unit (In Rs.)	Rate/Unit (In words)	Preference
169	Pulse Pharmaceuticals Pvt Ltd	1299b	Cholecalciferol Syp- Each 5ml to contain: Vitamin D3 60,000 IU/Vitamin D3 60,000 IU Nano, 5ml Bottle	1ml	Deksel Nano Syrup 60000 IU	5ml bottle	9.81/1ml	Rupees Three Paise Sixty Only	L-3

END OF RATE CONTRACT

क.रा.बी.नि.  
ESIC